March 12, 2012
The National Institute for Health and Clinical Excellence (NICE) on Friday recommended Merck & Co.'s new hepatitis C drug Victrelis (boceprevir) for use in Britain's state health service. Although it often shuns expensive new treatments on cost grounds, NICE noted that the significant improvements seen with Victrelis make it a cost-effective option. Victrelis costs £30,800 (US $48,109) for a 44-week regimen; it is designed to be administered with peginterferon-alfa and ribavirin, which add £11,000 (US $17,178) to the total. The draft guidelines are open for consultation before final approval.
Adapted from:
Reuters
03.08.2012
No comments have been made.
|
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
![]() | Separate and Unequal Access Frames Discussion at CROI Panel on U.S. HIV Care Cascade |
![]() | CROI 2018: Highlights and What's Next for Advocates |
![]() | Reported PrEP 'Failure' Most Likely a Lack of Proper Testing and Adherence |
![]() | Injection Drug Use Among People Living With HIV: A Missed Opportunity to Save Lives |
![]() | Statin Use Might Reduce Risk of Cancer in HIV-Positive People |
![]() | Insurers and Pharmas Must Help Fix HIV Drug Pricing System, Advocates Say |